SIRPA and neutropenia: As expected from the physiology of CD47 expression, hematologic changes were the most common grade 3 or higher TRAEs; neutropenia (6.5%) and thrombocytopenia (8.3%) were the most common in anti-CD47 mAbs and selective SIRPα blockers, respectively.